VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

• Vertex obtains an exclusive license to TreeFrog's C-Stem^TM  manufacturing technology in type 1 diabetes 
• TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells 

BOSTON and BORDEAUX, France, April 23, 2024 /CNW/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem^TM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies.

TreeFrog-Release

TreeFrog's proprietary technology platform, C-Stem™, is designed to mimic the natural microenvironment, allowing cells to grow exponentially in 3D. The technology will enhance Vertex's ability to generate large amounts of fully differentiated cells for its portfolio of T1D cell therapies.

"Our goal is to transform the treatment of T1D, and our stem cell-derived, fully differentiated islet cell  VX-880 Ph 1/2  program has demonstrated this potential," said Morrey Atkinson Ph.D., Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, at Vertex. "We're excited to explore TreeFrog's C-Stem^TM to scale up stem cell production and deliver for the large number of people living with T1D."

"We are delighted to partner with Vertex Pharmaceuticals, the clear leader in cell therapy for T1D. This is a fantastic opportunity to apply and further develop our C-Stem™ technology for a first-in-class cell therapy treatment which could meet a huge unmet need," said Frédéric Desdouits, Ph.D., CEO of TreeFrog Therapeutics. "This collaboration with Vertex advances our business strategy of helping bring best-in-class cell therapies to millions of people — both through our own therapeutic programs, and with best-in-class partners like Vertex. We look forward to combining TreeFrog's extensive experience in cell therapy production and biology with Vertex's renowned expertise in T1D and cell therapy to bring these transformative therapies to patients."

About the Transaction

Under the agreement, TreeFrog will receive a $25M upfront payment, an equity investment from Vertex and up to $215M in milestones paid in connection with the development of a scaled-up process for fully differentiated islet cells. TreeFrog is also eligible to receive an additional $540M in clinical, regulatory and commercial milestones on up to two future products and tiered single digit royalties. Vertex will fund all research and development costs related to the collaboration. Vertex will be responsible for all development and commercialization of its cell therapies.

About Vertex

Visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

About TreeFrog Therapeutics

TreeFrog Therapeutics is a French-based biotech company set to unlock access to cell therapies for millions of patients. www.treefrog.fr

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements by Morrey Atkinson, Ph.D., and Frédéric Desdouits, Ph.D., in this press release, statements about the terms of and expectations for Vertex's collaboration with TreeFrog, potential benefits and results that may be achieved through the collaboration to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies, including the expectation that the technology will enhance Vertex's ability to generate large amounts of fully differentiated cells, statements regarding the future activities of the parties pursuant to the collaboration, and statements regarding upfront and milestone payments, Vertex's expected equity investment in TreeFrog and potential royalties on future products. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the anticipated benefits and potential of Vertex's collaboration with TreeFrog may not be achieved on the anticipated timeline, or at all, that data may not support further development of the therapies subject to the collaboration due to safety, efficacy, or other reasons, and other risks listed under the heading "Risk Factors" in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through Vertex's website at www.vrtx.com and on the SEC's website at www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

TreeFrog Therapeutics

Rachel Mooney
Chief Communications Officer
[email protected] 

PDF - https://mma.prnewswire.com/media/2394272/TreeFrog_Release.pdf
Logo - https://mma.prnewswire.com/media/2394267/TreeFrog_Therapeutics_and_VERTEX_Logo.jpg

SOURCE TreeFrog Therapeutics

Rachel Mooney, Tel: [phone], Vertex Pharmaceuticals Incorporated, Investors: [email protected] or 617-961-7163 Media: [email protected] or U.S.: 617-341-6992, or Heather Nichols: [phone] or International: [phone]